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DRUG (RE) DISCOVERY
FROM BENCH TO SPORT SIDE
BY LOVRO ZIBERNA
Drug discovery makes our lives different. We can live longer and healthier lives, 
and moreover enhance normal physiology to 
perform better. But on the other hand, we are 
also exposed to adverse and toxic effects of 
drug compounds. Therefore, modern clinical 
pharmacology puts enormous emphasis on the 
risk versus benefit debate. The dilemma is well-
defined when dealing with patients, as benefits 
in treating the disease usually overcome the risk 
of employing pharmacological treatment; how-
ever, when top athletes are involved, the benefit 
of going into a supra-physiological state endan-
gers health and is morally wrong. At the same 
time, some might argue that allowing doping 
would induce an equal playing field. This idea 
is not only absurd, but plainly irresponsible if 
risks to health are considered. 
In the age of fame and fortune, pharmacologi-
cal compounds play an important role in pro-
fessional sports. But – and this must be some-
thing common to human nature – athletes are 
not the only ones using performance enhanc-
ing substances: i) movie actors, singers, show 
business people, and college students use drug 
compounds to help them sculpt their bodies in a 
relatively short time; ii) classic musicians, who 
can use beta-blockers to improve their on-stage 
performance; iii) medical and law students, who 
use nootropics and amphetamines to enhance 
cognitive performance before important exams; 
iv) army soldiers, who are given special doping 
treatments to increase their endurance before 
engaging in battles; v) other professionals, who 
must meet tight deadlines and need to work be-
yond exhaustion. However, regulations – also 
called anti-doping rules – exist only in profes-
sional sports. One can look at these as specif-
ic rules of the game, and breaking those rules 
makes you a cheat. If caught, you are eliminated. 
The other doping-spoiled disciplines in modern 
society don’t have such rules. For instance, it’s 
hard to imagine a college student undergoing a 
doping test before taking a written exam, even 
though if he has doped, he would have gained 
an unfair advantage over his peers. Top scores 
achieved in exams have an impact on future 
career opportunities of the students; similarly, 
winning sports competitions influences the fu-
ture of top athletes. 
DRUG DISCOVERY: HOPE FOR PATIENTS, BURDEN 
FOR ATHLETES
The role of scientists is to identify new molecu-
lar targets for existing pathologies, and to pro-
vide novel pharmacological solutions. Howev-
er, such noble work can be misused for cheating 
purposes since the same drug therapy, used to 
treat diseases, can also have a performance-en-
hancing effect when used by healthy individu-
als. For example, gene therapy that effectively 
alleviates symptoms of patients with muscular 
dystrophy could also be used as gene doping for 
increasing the muscle strength of athletes. But, 
it is not the concern of scientists involved in the 
drug discovery process whether the athletes will 
abuse their findings. Research work must remain 
disease-oriented, and nothing should inhibit the 
time needed for a drug to reach the patients. 
FROM DRUG DISCOVERY TO DOPING
On the other side, within the so-called doping 
society, one can only follow latest research de-
velopments and try to implement them before 
the anti-doping scientific community identify 
the risk and develop appropriate analytical 
methods to detect performance-enhancing com-
pounds. By doing this, they remain undetected 
while training and competing in an enhanced 
state. This is the most crucial time window for 
doped athletes. As an example, erythropoietin 
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(EPO) was first introduced to the market in 
1989, but the first analytical method appeared 
only as late as in the year 2000. An even more 
dramatic story is related to recombinant human 
growth hormone (hGH), which was developed 
in 1981, but its detection was introduced in 2004. 
However, further analytical improvements were 
needed, thus the first completed case involving 
an analytical finding for hGH happened only in 
2010. Similarly, certain performance-enhancing 
compounds are currently either in clinical test-
ing or on the market, but without proper analyti-
cal tests developed to detect them. 
To try to bypass this time window, all collect-
ed samples are currently being stored for the pe-
riod of 10 years, and can be re-tested later upon 
the discovery of new performance-enhancing 
compounds, or upon advances of analytical ap-
proaches. 
Why is anti-doping one step behind the dop-
ing society? It can be speculated that informa-
tion leaks out of pharmaceutical industry labo-
ratories as early as drugs enter into pre-clinical 
testing. But even this is not necessarily true, 
since many ideas can be found using patent 
searching, reading research posters during sci-
entific conferences, reading scientific papers, 
or by browsing through on-going worldwide 
clinical trials which are freely accessible online 
(at clinicaltrials.gov). It can be hypothesized, 
as shown by Figure 2, that the numbers of po-
tential dopers increase as the clinical studies 
advance into Phase II or Phase III. It is worth 
noticing that during the Phase III, tested drugs 
are sent to many clinical institutes worldwide. 
Tracking the drugs is difficult, and the poten-
tial abuse of athletes easier. Medical knowledge 
within the doping society is the key factor that 
enables athletic enhancement; thus, of course, 
considerable human resources are needed to 
run this efficiently. History has taught us that 
top-level athletes using performance-enhancing 
drugs usually have a strong interdisciplinary 
team around them, consisting of different pro-
fessionals, such as medical doctors, pharma-
cists, nurses, endurance physiologists, coaches, 
team managers, and many others. 
WHAT CAN ANTI-DOPING SOCIETY DO: IF YOU 
CAN’T BEAT THEM, JOIN THEM?
There are many approaches that can be em-
ployed in improving the fight against doping. 
The most obvious is to improve the analytical 
methods: faster analysis, higher sensitivity and 
stronger proof. In the same manner, tight col-
laboration with the pharmaceutical industry can 
help scientists develop early detection methods 
for drugs with performance-enhancing poten-
tial in sports. This has recently been put into 
practice as the drug company GlaxoSmithKline 
has signed a deal with the World Anti-Doping 
Agency (WADA) in July 2011. The company 
agreed to supply confidential information about 
medicines in early stages of development that 
may be abused by athletes once licensed. We 
Figure 1. Scheme showing the parties involved in the drug discovery process. From the doping 
perspective, there are two options: a) Therapeutic pathway – from bench to bedside; b) Doping 
pathway – from bench to sport side. 
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can expect that WADA will try to sign similar 
deals with other big companies. 
In addition, we must create a strong scientific 
team, as part of WADA’s department or even as 
an independent non-governmental organization, 
that would screen all the latest research in the 
pre-clinical and clinical spheres – similarly to 
how doping society is screening for new ideas. 
This approach – scientific guard watching – can 
identify so-called “hot spots”. Any new drugs 
found to have performance-enhancing potential 
would then be highlighted to WADA, which 
could coordinate the research activities of an-
ti-doping research groups. Even more, such a 
scientific team could speculate on molecular 
mechanisms involved in athletic enhancement 
before the actual drug discovery – this could be 
a revolutionary transformation from “one step 
behind” to “one step ahead”. 
Furthermore, intelligence gathered from ev-
eryone involved in sports, and elsewhere, can 
help anti-doping authorities to target drug test-
ing of the athletes. It is important to get state-
of-the-art knowledge from banned athletes, and 
others involved in the doping business. Similar 
approaches have been successfully employed in 
drug trafficking, as well as in gathering intel-
ligence used by the military.  
Lastly, much more emphasis must be put on 
education of young athletes. Many recently 
started educational programs have successfully 
raised doping awareness by highlighting nega-
tive health consequences, the cheating aspect, 
and the possibility of getting caught.
CONCLUSION
Nowadays, athletes believe that medically su-
pervised doping is protecting them against seri-
ous adverse/toxic effects of drugs. But there is 
a catch: not all toxic effects appear acutely, and 
many serious ones must be considered in the 
mid- and long-term. Furthermore, participation 
of medical doctors in doping is against the ba-
sic principles of medicine, morally and legally. 
Pharmacology should be used to treat patients, 
and not to transform athletic competition into 
a competition between research teams, pharma-
ceutical companies, or even medical doctors. 
Figure 2. This hypothetical diagram shows the appearance of a novel compound, with perfor-
mance-enhancing properties, from a drug discovery process into sports. Please note that this 
figure represents the author’s personal predictions, and therefore does not reflect the actual situ-
ation, since there is no data available for the exact evaluation. 
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